Drug Trial Radar · NCT04704999
Southeast Asia Dose Optimization of Tafenoquine
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
820
Planned (sponsor's estimate)
Start
Jul 22, 2024
Primary completion
Oct 4, 2027
Study completion Feb 7, 2028
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia. Addendum for Indonesia: The INSPECTOR trial results showed that tafenoquine 300mg was not efficacious for radical cure (79% probability for recurrence after treatment). The comparator arm, low-dose primaquine 3.5mg/kg divided equally over 14 days, showed a 48% probability of recurrence after treatment). The standard of care for radical cure in Indonesia is high-dose primaquine 7mg/kg divided in 7 daily doses).
Conditions
- Plasmodium Vivax Malaria
Interventions
TafenoquineDrug
Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
ChloroquineDrug
Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
Artemether 20 mg-Lumefantrine 120 mgDrug
Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
PrimaquineDrug
Primaquine will be given once daily over 7 days (7mg/kg total dose divided 1mg/kg/day) as per the national malaria guidelines.
Dihydroartemisinin 40 mg-Piperaquine 320 mgDrug
Dihydroartemisinin-piperaquine will be given once daily over 3 days. Whole tablets will be given based on weight bands.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microscopy positive P. vivax recurrence after radical treatment up to month 4Time frame: At month 4
Locations
6 sites in 5 countries. Site status is shown where the registry gives one.
Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia
Siem Reap, Cambodia · Recruiting
Oxford University Clinical Research Unit (OUCRU-Indonesia)
Jayapura, Indonesia · Not yet recruiting
Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
Vientiane, Laos · Recruiting
Mahidol Vivax Research Unit (MVRU)
Bangkok, Thailand · Recruiting
Shoklo Malaria Research Unit (SMRU)
Bangkok, Thailand · Recruiting
Oxford University Clinical Research Unit (OUCRU)
Bình Phước, Vietnam · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.